TVAR live edited broadcasts are safe.

Original title: The impact of live transmition on patients outcomes during transcatheter aortic valve replacement: Results fron the VERITAS study. Reference: Ron Waskman, et al. Cardiovascular Revascularization Medicine 2014;15:63-68

 

With the advancement of medical technology and the great development of telecommunications, performing live or edited cases has become a common occurrence in medical education, but one of the points of discussion was always the safety of these procedures. This is a multicentre, retrospective observational case-control study. The endpoint of this analysis was the safety of patients receiving percutaneous aortic valve replacement (TVAR) during live broadcasts. Valves used were, for femoral access CoreValve and for femoral or apical access, Edwards SAPIEN. Patients receiving TVAR during a live broadcast were compared with a control group using the following criteria; STS ± 2 points, day of the procedure ±4 weeks, same first surgeon and the same access resulting one control group of 46 patients and live stream group of 46 patients. The safety endpoint was evaluated by the rate of major complications: hospital death, stroke, tamponade, embolization, coronary obstruction, renal failure requiring dialysis and need for pacemaker.

No clinical or echocardiographic results from the group live stream versus the control group were observed. The total duration of the procedure was higher in the live broadcast group (129 ± 49 versus 100 ± 42 minutes p = 0.007) but no difference in fluoroscopy time, number of surgeons, intra procedural complications, stay in coronary unit or hospital. The presence of moderate or severe aortic regurgitation was 4.7 % in the live stream group and 9.5 % in the control group without reaching statistical significance. There were no differences in the safety endpoint, death (2.2 % in each group), conversion to surgery, vascular complications, bleeding, arrhythmias, need for pacemaker or dialysis infections.

Conclusion

These data provide support that procedures of percutaneous aortic valve replacement live broadcast for congress made

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....